![[Left] Woman contemplating the luck her four-leaf clover necklace could bring her. [Right] Four-leaf clover necklace left behind.](https://usim.beprod.ilarishcp.com/sites/ilarishcp_com/files/styles/webp/public/styles/common_width_576/public/2024-09/stills-m_4.jpeg.webp?itok=Yb1RmyAw)
Dosing and Administration
Not an actual patient. Individual results will vary.
ILARIS is the only FDA-approved once-monthly treatment in Still’s disease (SJIA and AOSD)1
ILARIS is dosed according to body weight with a recommended dose of 4 mg/kg (with a maximum of 300 mg) every 4 weeks for patients who weigh ≥7.5 kg1
ILARIS is given subcutaneously by a health care professional in 2 steps1
Step 1: Inspect
ILARIS solution has a concentration of 150 mg/mL — DO NOT SHAKE.
The solution should be:
- Essentially free from particulates
- Clear to opalescent
- Colorless to slightly brownish-yellow tint
DO NOT USE if the solution:
- Has a distinctly brown discoloration
- Is highly opalescent
- Contains visible particles
Step 2: Inject
Using a sterile 1-mL syringe and 18-gauge x 2” needle, carefully withdraw the required volume depending on the dose to be administered and subcutaneously inject using a 27-gauge x 0.5” needle.
Avoid injection into scar tissue as this may result in insufficient exposure to ILARIS.
Discard unused product or waste material in accordance with the local requirements.
Refer to the full Prescribing Information for detailed preparation and administration instructions.
ILARIS Dosing Guide
Download the Dosing Guide to view additional important information about administering ILARIS.
Reference: 1. Ilaris. Prescribing information. Novartis Pharmaceuticals Corp.